Federal program funds addiction treatment hubs in high-overdose communities
S. 665 — Fatal Overdose Reduction Act of 2025 · Filed by Maria Cantwell (D-WA) · 1 cosponsor · Introduced Feb 20, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a five-year federal demonstration program under Medicaid to fund 'Health Engagement Hubs'—drop-in centers in high-overdose communities that provide opioid and substance use disorder treatment, harm reduction supplies, mental health services, and wraparound social services (housing help, legal aid, employment counseling). States apply to participate; the federal government covers 90% of costs through a prospective payment system. The bill appropriates $60 million for planning grants, administration, and evaluation.
Why we flagged it
The bill's operative mechanism is a federal-state partnership to establish and fund community-based addiction treatment and harm reduction centers. It is a public health infrastructure investment, not a regulatory change, tax provision, or private subsidy.
What the text implies
- The bill requires at least 50% of hubs in high-overdose counties or mental health shortage areas, but does not mandate rural coverage—rural areas may be underserved if they fall outside these criteria, potentially widening geographic disparities in access.
- The prospective payment system is state-designed and state-administered; variation across states may create inconsistent service quality, reimbursement rates, and eligibility standards, making outcomes difficult to compare and potentially disadvantaging residents of lower-resourced states.
The full analysis lists 5 implications of this text.
Who stands to gain
Federally qualified health centers and community health centers (as partner organizations); Substance use disorder treatment providers and clinics (as partner organizations); Pharmaceutical manufacturers of opioid use disorder medications (buprenorphine, methadone, naltrexon